You searched for "atrophy"
FEVR characteristics
3 February 2023
| Fiona Rowe (Prof)
|
Paediatric Ophthalmology / Strabismus
The authors report a series of 16 cases of familial exudative vitreoretinopathy (FEVR) in Northern Ireland (NI) to characterise the genetic patterns and identify other common characteristics relevant for current and future practice. This was a retrospective study including 12...
Leber’s hereditary optic neuropathy outcomes in an Indian population
4 October 2023
| Fiona Rowe (Prof)
|
Paediatric Ophthalmology / Strabismus
A large cohort study in an Indian population is presented, with clinical and genetic profile analysis of patients with Leber’s hereditary optic neuropathy (LHON) treated over a five-year period. The study included 157 patients; 143 male, 14 female (10.2:1 ratio)...
ILM peeling techniques in myopic traction maculopathy
29 November 2024
| Kurt Spiteri Cornish
|
EYE - Vitreo-Retinal
Myopic traction maculopathy (MTM) is a sight-threatening complication of high myopia including macular retinoschisis (MRS) or foveoschisis, foveal detachment (FD) and myopic macular hole (MMH). Standard surgical treatment is vitrectomy with internal limiting membrane (ILM) peeling, but full-thickness macular hole...
First treatment for late-stage dry AMD rejected by UK drug regulator
Leading sight loss charity the Macular Society has responded to the decision not to approve the first potential treatment for geographic atrophy (GA) or late stage dry aged-related macular degeneration. The decision is a significant setback for those affected by...Risk factors for intraoperative floppy iris syndrome
Intraoperative floppy iris syndrome (IFIS) is charcterised by flaccid iris stroma leading to fluttering and billowing of iris, tendency of iris to prolapse through surgical incisions and causing intraoperative pupil constriction. IFIS is characterised as complete when all three features...Ten-year experience with intracameral chemotherapy for aqueous seeding in retinoblastoma: long-term efficacy, safety and toxicity
This is a retrospective review of all consecutive patients with primary (n=4) or secondary non-iatrogenic (n=16) aqueous seeding (AS) treated by intracameral chemotherapy (ICC) in Lausanne between 2011 and 2020 with a minimum follow-up of one year. Aqueous seeding control...Retrograde maculopathy in glaucoma
1 October 2017
| Chrysostomos D Dimitriou
|
EYE - Glaucoma
Macular optical coherence tomography (OCT) analysis can be used for quantitative measures of optic nerve atrophy at a location far away from the optic nerve head. This has recently led to the discovery of microcystic macular oedema (MME), in the...
Prostaglandin-associated periorbitopathy
1 February 2016
| James Hsuan
|
EYE - Glaucoma
This is a masked study of 33 patients who had been taking a prostaglandin analogue in one eye only for at least a year, to look for signs of prostaglandin-associated periorbitopathy (PAP). The investigators devised a new grading system to...
Is virtual reality perimetry as reliable as static perimetry in detecting neurological visual field loss?
1 July 2024
| Claire Howard
|
EYE - Neuro-ophthalmology
This study compares agreement between virtual reality perimetry (VRP) and static automated perimetry (SAP) in a variety of neuro-ophthalmological conditions. For this work the Order of Magnitude (OM) VR-based visual field assessment system was used which has been developed by...
Amyotrophic lateral sclerosis (ALS): what happens to eye movements?
3 February 2023
| Claire Howard
|
EYE - Neuro-ophthalmology
|
Eye movement, amyotrophic lateral sclerosis, anti-saccades; biomarker, pursuit, saccades
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder of upper motor neurons of the corticospinal tract and lower motor neurons in brainstem nuclei and the anterior horn of the spinal cord. Limited literature is available on abnormal ocular movements in...
Vision loss during Eylea treatment for AMD
1 December 2017
| Saruban Pasu
|
EYE - Vitreo-Retinal
This report investigated patients who lost more than two lines of vision despite periodic injections of aflibercept and explored the factors associated with vision loss. One hundred and ninety-six eyes were included in this study over a two year period....
Combined anti-VEGF and PDT for wet AMD
1 February 2014
| Brian Ang
|
EYE - Vitreo-Retinal
The authors report on a retrospective case series of combined anti-VEGF and photodynamic therapy (PDT) in the treatment of wet age-related macular degeneration (AMD) refractory to anti-VEGF monotherapy alone. The criteria for treatment failure of anti-VEGF monotherapy were persistent subretinal...